Copyright Reports & Markets. All rights reserved.

Global PD-1 and PD-L1 Inhibitors Market Insights and Forecast to 2027

Request for Sample of this report
Buy now

1 Study Coverage

  • 1.1 PD-1 and PD-L1 Inhibitors Product Introduction
  • 1.2 Market by Type
    • 1.2.1 Global PD-1 and PD-L1 Inhibitors Market Size Growth Rate by Type
    • 1.4.2 PD-1 Inhibitors
    • 1.4.3 PD-L1 Inhibitors
  • 1.3 Market by Application
    • 1.3.1 Global PD-1 and PD-L1 Inhibitors Market Size Growth Rate by Application
    • 1.3.2 Solid Tumors
    • 1.3.3 Blood-related Tumors
  • 1.4 Study Objectives
  • 1.5 Years Considered

2 Executive Summary

  • 2.1 Global PD-1 and PD-L1 Inhibitors Sales Estimates and Forecasts 2016-2027
  • 2.2 Global PD-1 and PD-L1 Inhibitors Revenue Estimates and Forecasts 2016-2027
  • 2.3 Global PD-1 and PD-L1 Inhibitors Revenue by Region: 2016 VS 2021 VS 2027
  • 2.4 Global Top PD-1 and PD-L1 Inhibitors Regions by Sales
    • 2.4.1 Global Top PD-1 and PD-L1 Inhibitors Regions by Sales (2016-2021)
    • 2.4.2 Global Top PD-1 and PD-L1 Inhibitors Regions by Sales (2022-2027)
  • 2.5 Global Top PD-1 and PD-L1 Inhibitors Regions by Revenue
    • 2.5.1 Global Top PD-1 and PD-L1 Inhibitors Regions by Revenue (2016-2021)
    • 2.5.2 Global Top PD-1 and PD-L1 Inhibitors Regions by Revenue (2022-2027)
  • 2.6 North America
  • 2.7 Europe
  • 2.8 Asia-Pacific
  • 2.9 Latin America
  • 2.10 Middle East & Africa

3 Competition by Manufacturers

  • 3.1 Global PD-1 and PD-L1 Inhibitors Sales by Manufacturers
    • 3.1.1 Global Top PD-1 and PD-L1 Inhibitors Manufacturers by Sales (2016-2021)
    • 3.1.2 Global Top PD-1 and PD-L1 Inhibitors Manufacturers Market Share by Sales (2016-2021)
    • 3.1.3 Global Top 10 and Top 5 Companies by PD-1 and PD-L1 Inhibitors Sales in 2020
  • 3.2 Global PD-1 and PD-L1 Inhibitors Revenue by Manufacturers
    • 3.2.1 Global Top PD-1 and PD-L1 Inhibitors Manufacturers by Revenue (2016-2021)
    • 3.2.2 Global Top PD-1 and PD-L1 Inhibitors Manufacturers Market Share by Revenue (2016-2021)
    • 3.2.3 Global Top 10 and Top 5 Companies by PD-1 and PD-L1 Inhibitors Revenue in 2020
  • 3.3 Global PD-1 and PD-L1 Inhibitors Sales Price by Manufacturers
  • 3.4 Analysis of Competitive Landscape
    • 3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
    • 3.4.2 Global PD-1 and PD-L1 Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    • 3.4.3 Global PD-1 and PD-L1 Inhibitors Manufacturers Geographical Distribution
  • 3.5 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type

  • 4.1 Global PD-1 and PD-L1 Inhibitors Sales by Type
    • 4.1.1 Global PD-1 and PD-L1 Inhibitors Historical Sales by Type (2016-2021)
    • 4.1.2 Global PD-1 and PD-L1 Inhibitors Forecasted Sales by Type (2022-2027)
    • 4.1.3 Global PD-1 and PD-L1 Inhibitors Sales Market Share by Type (2016-2027)
  • 4.2 Global PD-1 and PD-L1 Inhibitors Revenue by Type
    • 4.2.1 Global PD-1 and PD-L1 Inhibitors Historical Revenue by Type (2016-2021)
    • 4.2.2 Global PD-1 and PD-L1 Inhibitors Forecasted Revenue by Type (2022-2027)
    • 4.2.3 Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Type (2016-2027)
  • 4.3 Global PD-1 and PD-L1 Inhibitors Price by Type
    • 4.3.1 Global PD-1 and PD-L1 Inhibitors Price by Type (2016-2021)
    • 4.3.2 Global PD-1 and PD-L1 Inhibitors Price Forecast by Type (2022-2027)

5 Market Size by Application

  • 5.1 Global PD-1 and PD-L1 Inhibitors Sales by Application
    • 5.1.1 Global PD-1 and PD-L1 Inhibitors Historical Sales by Application (2016-2021)
    • 5.1.2 Global PD-1 and PD-L1 Inhibitors Forecasted Sales by Application (2022-2027)
    • 5.1.3 Global PD-1 and PD-L1 Inhibitors Sales Market Share by Application (2016-2027)
  • 5.2 Global PD-1 and PD-L1 Inhibitors Revenue by Application
    • 5.2.1 Global PD-1 and PD-L1 Inhibitors Historical Revenue by Application (2016-2021)
    • 5.2.2 Global PD-1 and PD-L1 Inhibitors Forecasted Revenue by Application (2022-2027)
    • 5.2.3 Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Application (2016-2027)
  • 5.3 Global PD-1 and PD-L1 Inhibitors Price by Application
    • 5.3.1 Global PD-1 and PD-L1 Inhibitors Price by Application (2016-2021)
    • 5.3.2 Global PD-1 and PD-L1 Inhibitors Price Forecast by Application (2022-2027)

6 North America

  • 6.1 North America PD-1 and PD-L1 Inhibitors Market Size by Type
    • 6.1.1 North America PD-1 and PD-L1 Inhibitors Sales by Type (2016-2027)
    • 6.1.2 North America PD-1 and PD-L1 Inhibitors Revenue by Type (2016-2027)
  • 6.2 North America PD-1 and PD-L1 Inhibitors Market Size by Application
    • 6.2.1 North America PD-1 and PD-L1 Inhibitors Sales by Application (2016-2027)
    • 6.2.2 North America PD-1 and PD-L1 Inhibitors Revenue by Application (2016-2027)
  • 6.3 North America PD-1 and PD-L1 Inhibitors Market Size by Country
    • 6.3.1 North America PD-1 and PD-L1 Inhibitors Sales by Country (2016-2027)
    • 6.3.2 North America PD-1 and PD-L1 Inhibitors Revenue by Country (2016-2027)
    • 6.3.3 U.S.
    • 6.3.4 Canada

7 Europe

  • 7.1 Europe PD-1 and PD-L1 Inhibitors Market Size by Type
    • 7.1.1 Europe PD-1 and PD-L1 Inhibitors Sales by Type (2017-2027)
    • 7.1.2 Europe PD-1 and PD-L1 Inhibitors Revenue by Type (2017-2027)
  • 7.2 Europe PD-1 and PD-L1 Inhibitors Market Size by Application
    • 7.2.1 Europe PD-1 and PD-L1 Inhibitors Sales by Application (2017-2027)
    • 7.2.2 Europe PD-1 and PD-L1 Inhibitors Revenue by Application (2017-2027)
  • 7.3 Europe PD-1 and PD-L1 Inhibitors Market Size by Country
    • 7.3.1 Europe PD-1 and PD-L1 Inhibitors Sales by Country (2017-2027)
    • 7.3.2 Europe PD-1 and PD-L1 Inhibitors Revenue by Country (2017-2027)
    • 7.3.3 Germany
    • 7.3.4 France
    • 7.3.5 U.K.
    • 7.3.6 Italy
    • 7.3.7 Russia

8 Asia Pacific

  • 8.1 Asia Pacific PD-1 and PD-L1 Inhibitors Market Size by Type
    • 8.1.1 Asia Pacific PD-1 and PD-L1 Inhibitors Sales by Type (2018-2027)
    • 8.1.2 Asia Pacific PD-1 and PD-L1 Inhibitors Revenue by Type (2018-2027)
  • 8.2 Asia Pacific PD-1 and PD-L1 Inhibitors Market Size by Application
    • 8.2.1 Asia Pacific PD-1 and PD-L1 Inhibitors Sales by Application (2018-2027)
    • 8.2.2 Asia Pacific PD-1 and PD-L1 Inhibitors Revenue by Application (2018-2027)
  • 8.3 Asia Pacific PD-1 and PD-L1 Inhibitors Market Size by Region
    • 8.3.1 Asia Pacific PD-1 and PD-L1 Inhibitors Sales by Region (2018-2027)
    • 8.3.2 Asia Pacific PD-1 and PD-L1 Inhibitors Revenue by Region (2018-2027)
    • 8.3.3 China
    • 8.3.4 Japan
    • 8.3.5 South Korea
    • 8.3.6 India
    • 8.3.7 Australia
    • 8.3.8 Taiwan
    • 8.3.9 Indonesia
    • 8.3.10 Thailand
    • 8.3.11 Malaysia
    • 8.3.12 Philippines

9 Latin America

  • 9.1 Latin America PD-1 and PD-L1 Inhibitors Market Size by Type
    • 9.1.1 Latin America PD-1 and PD-L1 Inhibitors Sales by Type (2019-2027)
    • 9.1.2 Latin America PD-1 and PD-L1 Inhibitors Revenue by Type (2019-2027)
  • 9.2 Latin America PD-1 and PD-L1 Inhibitors Market Size by Application
    • 9.2.1 Latin America PD-1 and PD-L1 Inhibitors Sales by Application (2019-2027)
    • 9.2.2 Latin America PD-1 and PD-L1 Inhibitors Revenue by Application (2019-2027)
  • 9.3 Latin America PD-1 and PD-L1 Inhibitors Market Size by Country
    • 9.3.1 Latin America PD-1 and PD-L1 Inhibitors Sales by Country (2019-2027)
    • 9.3.2 Latin America PD-1 and PD-L1 Inhibitors Revenue by Country (2019-2027)
    • 9.3.3 Mexico
    • 9.3.4 Brazil
    • 9.3.5 Argentina

6 Middle East and Africa

  • 6.1 Middle East and Africa PD-1 and PD-L1 Inhibitors Market Size by Type
    • 6.1.1 Middle East and Africa PD-1 and PD-L1 Inhibitors Sales by Type (2016-2027)
    • 6.1.2 Middle East and Africa PD-1 and PD-L1 Inhibitors Revenue by Type (2016-2027)
  • 6.2 Middle East and Africa PD-1 and PD-L1 Inhibitors Market Size by Application
    • 6.2.1 Middle East and Africa PD-1 and PD-L1 Inhibitors Sales by Application (2016-2027)
    • 6.2.2 Middle East and Africa PD-1 and PD-L1 Inhibitors Revenue by Application (2016-2027)
  • 6.3 Middle East and Africa PD-1 and PD-L1 Inhibitors Market Size by Country
    • 6.3.1 Middle East and Africa PD-1 and PD-L1 Inhibitors Sales by Country (2016-2027)
    • 6.3.2 Middle East and Africa PD-1 and PD-L1 Inhibitors Revenue by Country (2016-2027)
    • 6.3.3 Turkey
    • 6.3.4 Saudi Arabia
    • 6.3.5 UAE

11 Company Profiles

  • 11.1 Merck
    • 11.1.1 Merck Corporation Information
    • 11.1.2 Merck Overview
    • 11.1.3 Merck PD-1 and PD-L1 Inhibitors Sales, Price, Revenue and Gross Margin (2016-2021)
    • 11.1.4 Merck PD-1 and PD-L1 Inhibitors Product Description
    • 11.1.5 Merck Related Developments
  • 11.2 Bristol-Myers Squibb
    • 11.2.1 Bristol-Myers Squibb Corporation Information
    • 11.2.2 Bristol-Myers Squibb Overview
    • 11.2.3 Bristol-Myers Squibb PD-1 and PD-L1 Inhibitors Sales, Price, Revenue and Gross Margin (2016-2021)
    • 11.2.4 Bristol-Myers Squibb PD-1 and PD-L1 Inhibitors Product Description
    • 11.2.5 Bristol-Myers Squibb Related Developments
  • 11.3 Roche
    • 11.3.1 Roche Corporation Information
    • 11.3.2 Roche Overview
    • 11.3.3 Roche PD-1 and PD-L1 Inhibitors Sales, Price, Revenue and Gross Margin (2016-2021)
    • 11.3.4 Roche PD-1 and PD-L1 Inhibitors Product Description
    • 11.3.5 Roche Related Developments
  • 11.4 AstraZeneca
    • 11.4.1 AstraZeneca Corporation Information
    • 11.4.2 AstraZeneca Overview
    • 11.4.3 AstraZeneca PD-1 and PD-L1 Inhibitors Sales, Price, Revenue and Gross Margin (2016-2021)
    • 11.4.4 AstraZeneca PD-1 and PD-L1 Inhibitors Product Description
    • 11.4.5 AstraZeneca Related Developments
  • 11.5 Ono Pharmaceutical
    • 11.5.1 Ono Pharmaceutical Corporation Information
    • 11.5.2 Ono Pharmaceutical Overview
    • 11.5.3 Ono Pharmaceutical PD-1 and PD-L1 Inhibitors Sales, Price, Revenue and Gross Margin (2016-2021)
    • 11.5.4 Ono Pharmaceutical PD-1 and PD-L1 Inhibitors Product Description
    • 11.5.5 Ono Pharmaceutical Related Developments
  • 11.6 Regeneron
    • 11.6.1 Regeneron Corporation Information
    • 11.6.2 Regeneron Overview
    • 11.6.3 Regeneron PD-1 and PD-L1 Inhibitors Sales, Price, Revenue and Gross Margin (2016-2021)
    • 11.6.4 Regeneron PD-1 and PD-L1 Inhibitors Product Description
    • 11.6.5 Regeneron Related Developments
  • 11.7 Innovent
    • 11.7.1 Innovent Corporation Information
    • 11.7.2 Innovent Overview
    • 11.7.3 Innovent PD-1 and PD-L1 Inhibitors Sales, Price, Revenue and Gross Margin (2016-2021)
    • 11.7.4 Innovent PD-1 and PD-L1 Inhibitors Product Description
    • 11.7.5 Innovent Related Developments
  • 11.8 Hengrui Medicine
    • 11.8.1 Hengrui Medicine Corporation Information
    • 11.8.2 Hengrui Medicine Overview
    • 11.8.3 Hengrui Medicine PD-1 and PD-L1 Inhibitors Sales, Price, Revenue and Gross Margin (2016-2021)
    • 11.8.4 Hengrui Medicine PD-1 and PD-L1 Inhibitors Product Description
    • 11.8.5 Hengrui Medicine Related Developments
  • 11.9 Junshi Biosciences
    • 11.9.1 Junshi Biosciences Corporation Information
    • 11.9.2 Junshi Biosciences Overview
    • 11.9.3 Junshi Biosciences PD-1 and PD-L1 Inhibitors Sales, Price, Revenue and Gross Margin (2016-2021)
    • 11.9.4 Junshi Biosciences PD-1 and PD-L1 Inhibitors Product Description
    • 11.9.5 Junshi Biosciences Related Developments
  • 11.10 Merck KGaA
    • 11.10.1 Merck KGaA Corporation Information
    • 11.10.2 Merck KGaA Overview
    • 11.10.3 Merck KGaA PD-1 and PD-L1 Inhibitors Sales, Price, Revenue and Gross Margin (2016-2021)
    • 11.10.4 Merck KGaA PD-1 and PD-L1 Inhibitors Product Description
    • 11.10.5 Merck KGaA Related Developments
  • 11.1 Merck
    • 11.1.1 Merck Corporation Information
    • 11.1.2 Merck Overview
    • 11.1.3 Merck PD-1 and PD-L1 Inhibitors Sales, Price, Revenue and Gross Margin (2016-2021)
    • 11.1.4 Merck PD-1 and PD-L1 Inhibitors Product Description
    • 11.1.5 Merck Related Developments

12 Value Chain and Sales Channels Analysis

  • 12.1 PD-1 and PD-L1 Inhibitors Value Chain Analysis
  • 12.2 PD-1 and PD-L1 Inhibitors Key Raw Materials
    • 12.2.1 Key Raw Materials
    • 12.2.2 Raw Materials Key Suppliers
  • 12.3 PD-1 and PD-L1 Inhibitors Production Mode & Process
  • 12.4 PD-1 and PD-L1 Inhibitors Sales and Marketing
    • 12.4.1 PD-1 and PD-L1 Inhibitors Sales Channels
    • 12.4.2 PD-1 and PD-L1 Inhibitors Distributors
  • 12.5 PD-1 and PD-L1 Inhibitors Customers

13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis

  • 13.1 PD-1 and PD-L1 Inhibitors Industry Trends
  • 13.2 PD-1 and PD-L1 Inhibitors Market Drivers
  • 13.3 PD-1 and PD-L1 Inhibitors Market Challenges
  • 13.4 PD-1 and PD-L1 Inhibitors Market Restraints

14 Key Findings in The Global PD-1 and PD-L1 Inhibitors Study

    15 Appendix

    • 15.1 Research Methodology
      • 15.1.1 Methodology/Research Approach
      • 15.1.2 Data Source
    • 15.2 Author Details

    PD-1 and PD-L1 Inhibitors market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global PD-1 and PD-L1 Inhibitors market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2016-2027.

    Segment by Type
    PD-1 Inhibitors
    PD-L1 Inhibitors

    Segment by Application
    Solid Tumors
    Blood-related Tumors

    By Company
    Merck
    Bristol-Myers Squibb
    Roche
    AstraZeneca
    Ono Pharmaceutical
    Regeneron
    Innovent
    Hengrui Medicine
    Junshi Biosciences
    Merck KGaA

    By Region
    North America
    U.S.
    Canada
    Europe
    Germany
    France
    U.K.
    Italy
    Russia
    Asia-Pacific
    China
    Japan
    South Korea
    India
    Australia
    Taiwan
    Indonesia
    Thailand
    Malaysia
    Philippines
    Vietnam
    Latin America
    Mexico
    Brazil
    Argentina
    Middle East & Africa
    Turkey
    Saudi Arabia

    Buy now